AVAI BIO, INC.
corporate_fare Company Profile
AVAI BIO, INC. (OTC:AVAI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for AVAI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 7/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for AVAI spans 10-Q, 10-K, 8-K.
Recent high-impact activity:
- Avaí Bio Hits Key Milestone: Klotho-Producing Cells Successfully Encapsulated and Secreting
- AVAI Bio Posts $552K Quarterly Loss, Cash Rises to $84K, Going Concern Lingers
- AVAI Bio 10-K Flags Going Concern Doubt, $1.75M Loss, and Material Weaknesses
- AVAI BIO Terminates AI Healthcare Joint Venture with Ainnova Tech
- AVAI BIO Reports Substantial Doubt About Going Concern, Ineffective Controls, and Worsening Financials
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 4,409 shares in AVAI as of the September 15, 2026 settlement, a 100.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 61.1% of AVAI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.